More than 1 billion people worldwide are infected with helminths, with those living in resource-poor tropical areas disproportionately affected. Complex interactions between helminths and their host result in systemic effects on immunity, with a skewing towards type 2 responses and profound consequences on the host immune milieu^[@CR1]^. Type 2 responses suppress T helper 1 (T~H~1) cells and skew cytokine response profiles towards IL-4, IL-5, IL-9 and IL-13, which are produced by expanded populations of circulating T~H~2 cells and alternatively activated macrophages (AAMs)^[@CR1],[@CR2]^. Amplification of regulatory T (T~reg~) cell and regulatory B cell responses further inhibits host type 1 responses^[@CR1]^. Helminth-secreted immunomodulatory proteins induce IL-10 production and T~reg~ cell development and block the release of pro-inflammatory chemokines^[@CR3]^. Moreover, helminth-induced alterations of the gut microbiome also have systemic immunomodulatory effects^[@CR2]^. It has been demonstrated that helminth co-infection can influence the severity of viral infection in mice. Interestingly, in the case of murid herpesvirus 4 (MuHV-4) respiratory infection, prior infection with *Schistosoma mansoni* reduced disease severity^[@CR3]^. However, immune responses to pulmonary coronaviruses and MuHV-4 are different and therefore the impact of helminth co-infection may differ also.

COVID-19 is caused by the betacoronavirus SARS-CoV-2. In humans and mice infected with SARS-CoV, a closely related virus to SARS-CoV-2 and the causative agent of SARS, an extended duration of disease resulted in pulmonary fibrosis accompanied by perivascular infiltration and accumulation of AAMs, which are typically associated with type 2 responses^[@CR4]^. In mice given candidate SARS-CoV vaccines, pulmonary immunopathology was associated with eosinophil infiltration, which is also characteristic of a type 2 cellular immune response^[@CR5]^. Patients with COVID-19 who require admission to intensive care units typically have increased plasma concentrations of IL-2, IL-6, IL-7, IL-8, IL-17, G-CSF, CXCL10, CCL2, CCL3, CCL4, TNF and IFNγ compared with those with milder disease. Notably, unlike patients with SARS, patients with COVID-19 also have elevated levels of the type 2 cytokines IL-4 and IL-10 (ref.^[@CR6]^). The involvement of type 2 responses in the immunopathology of SARS and COVID-19 is of concern when considering potential effects of helminth co-infection. We call on the research community to investigate the influence of helminth co-infection on COVID-19 outcomes as the pandemic spreads through the helminth-endemic regions of the word. Potential negative effects may influence recommendations on deworming.
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